Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both before and after surgery for high-risk prostate cancer, significantly ...

In this study, researchers aimed to determine whether adding apalutamide to ADT improves outcomes in high-risk prostate cancer compared to placebo plus ADT.

A phase 3 study shows promising results for the use of apalutamide in combination with surgery for the treatment of prostate ...

A new study published in The New England Journal of Medicine showed that when compared to androgen deprivation therapy (ADT) ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

Man reading pill bottle AAP and apalutamide may improve outcomes, compared with bicalutamide, in a subgroup of patients with prostate cancer receiving ADT and salvage radiation after radical ...

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. An updated analysis of patients in the SPARTAN ...

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the ...